

ULTOMIRIS (RAVULIZUMAB-CWVZ) PATIENT REFERRAL AND PRESCRIPTION SHEET

| Patient Information | | | |
|--|---------------|---|---|
| Patient Name: | | Date: | |
| DOB: | | Height: | <input type="checkbox"/> inches <input type="checkbox"/> cm |
| Allergies: | | Weight: | <input type="checkbox"/> lbs <input type="checkbox"/> kg |
| Primary Diagnosis | | | |
| Diagnosis | ICD-10 | Diagnosis | ICD-10 |
| <input type="checkbox"/> Paroxysmal Nocturnal Hemoglobinuria | D59.5 | <input type="checkbox"/> Generalized Myasthenia Gravis | G70.00 |
| <input type="checkbox"/> Atypical Hemolytic Uremic Syndrome | D59.39 | <input type="checkbox"/> Neuromyelitis Optica Spectrum Disorder | G36.0 |
| <input type="checkbox"/> Other: _____ | | | |
| Medication Order | | | |
| Loading Dose <input type="checkbox"/> Infuse 2400mg IV x 1 dose (pt weight 40-59kg) <input type="checkbox"/> Infuse 2700mg IV x 1 dose (pt weight 60-99kg) <input type="checkbox"/> Infuse 3000mg IV x 1 dose (pt weight ≥100kg) <input type="checkbox"/> Other _____ | | <input type="checkbox"/> Refills x one year from date of signature unless indicated below <input type="checkbox"/> _____ Refills | |
| Maintenance Dose <input type="checkbox"/> Infuse 3000 mg IV every 8 weeks after loading dose (pt weight 40-59kg) <input type="checkbox"/> Infuse 3300 mg IV every 8 weeks after loading dose (pt weight 60-99kg) <input type="checkbox"/> Infuse 3600mg IV every 8 weeks after loading dose (pt weight ≥100kg) <input type="checkbox"/> Other _____ | | | |
| Nursing Orders Skilled nursing visit for clinical assessment, administration of medication. Initiate plan of treatment for ongoing nursing services. Insert or access and maintain access device as indicated in Ancillary Orders. Remove peripheral IV or access from implanted VAD when infusion is completed. | | | |
| Ancillary Orders | | | |
| Pre-medications: <input type="checkbox"/> Diphenhydramine: 25mg PO 30 min pre-infusion <input type="checkbox"/> Acetaminophen: 650mg PO 30 min pre-infusion <input type="checkbox"/> Famotidine: 20 mg PO x1 dose <input type="checkbox"/> Other pre-meds: _____ <input type="checkbox"/> Refill x one year | | IV Flush Orders: <input type="checkbox"/> Peripheral: NS 1-3 mL before/after use <input type="checkbox"/> Implanted VAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw. Heparin (100 unit/mL) 3 to 5 mL final flush <input type="checkbox"/> CVAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw Heparin (10 units/mL) 3 to 5 mL final flush <input type="checkbox"/> Refill x one year | |
| <input type="checkbox"/> Anaphylaxis Protocol: Epinephrine Auto-Injector dual pack: Adult: 0.3mg Children: 0.15 mg Administer epinephrine IM in the event of anaphylaxis. May repeat x 1 as needed, Call 911. Refill x 1yr | | | |
| Therapy Specific Documentation | | Other Required Documentation | |
| Please include the following lab results <input type="checkbox"/> MuSK Test <input type="checkbox"/> ACHR Test <input type="checkbox"/> MG-ADL Score <input type="checkbox"/> Meningococcal Vaccines (MenACWY and MenB) <input type="checkbox"/> Other _____ | | <input type="checkbox"/> Patient Demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise. <input type="checkbox"/> H&P OR progress note(s) <input type="checkbox"/> Medication List (include prior/failed DMARDS, biologics, or steroid use) | |
| Provider Information | | | |
| Provider Name: | | Provider Phone: | |
| Provider NPI: | | Provider Fax: | |
| Is the provider enrolled in Ultomiris REMS Program? If not, please register at www.ultsolrems.com | | | |
| Provider Address: | | | |

I authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription and any future refills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to KabaFusion.

Prescriber Signature: _____ Date: _____

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.